Laguna Blends Announces Addition of Soheil Samimi to the Board of Directors

March 10, 2017 – Escondido, CA – Laguna Blends Inc. (CSE: ISOL) (OTC: LAGBF) (FSE: LB6A.F) (the “Company” or “Laguna”) is pleased to announce that it has appointed Soheil Samimi to its Board of Directors effective immediately.

Mr. Samimi background includes management positions within leading technology companies, as well as being the successful founder of various start-ups which revolutionized the automated retail and digital media kiosk marketplace, working closely with major retailers, grocers, pharmacies and c-store chains in North America.

Soheil is currently serving as the CEO of a British-Columbia based company within the Canadian hemp and cannabis industry, with ventures for licensed production, clinics and retail operations, in addition to leading the largest distribution of non-psychoactive CBD products across Canada.

“Laguna wishes to welcome Mr. Samimi to team. We will look forward to leverage his overall experience to assist Laguna’s structuring through this current rapid growth phase, as well as assisting with the development of additional sales and distribution opportunities for the company’s products.”, stated Ray Grimm Jr., Laguna’s President and CEO.

The Company has also appointed Dianne Szigety as Corporate Secretary. Ms. Szigety is a fellow with the Institute of Chartered Secretaries and Administrators (ICSA) and brings over 25 years of management experience within the corporate and securities industry, providing corporate governance and compliance solutions to publicly traded companies. She has been a director and officer of several publicly traded and private companies.

The Company also announces the resignation of Rhys Williams from the Board of Directors. The Company is grateful for the contributions Mr. Williams brought to the Board and wish him the best moving forward.

About Isodiol International Inc.

Isodiol International, Inc. is the market leader in pharmaceutical grade cannabis compounds and the industry leader in manufacturing and development of consumer products. Isodiol’s nutraceutical division is the pioneer of many firsts for Hemp-derived cannabidiol (CBD), including 99% pure crystalline isolate, micro-encapsulation, and nano technology for the highest quality consumable and topical skin care products.

Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, seeking joint ventures and acquisitions to expand its portfolio of brands and subsidiaries and will aggressively continue International expansion into Latin America, Asia and Europe.

ON BEHALF OF THE BOARD

“Marcos Agramont” CEO & Director

COMPANY MEDIA:

Isodiol.com
CBDnaturals.com
Iso-sport
CBDskincream.com
Potocoffee

[email protected]
Join Us On Face Book: https://www.facebook.com/Isodiol/
Twitter: @isodiol

Forward-Looking Information:

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.